{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:19:14Z","timestamp":1788405554006,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The results of the MURANO trial showed encouraging progression-free survival (PFS) and overall survival (OS) in relapsed\/refractory chronic lymphocytic leukemia (RR-CLL) patients treated with venetoclax-rituximab (VEN-R). A retrospective analysis was performed to evaluate the efficacy and safety of VEN-R within the Polish Adult Leukemia Study Group (PALG) centers. The study group included 117 patients with RR-CLL (with early relapse after immunochemotherapy or bearing TP53 aberrations) treated with VEN-R in 2019\u20132023 outside clinical trials. Patients were treated with a median of 2 (range 1\u20139) previous lines of therapy. Twenty-two participants were previously treated with BTKi (18.8% out of 117). The median follow-up was 20.3\u00a0months (range 0.27\u201339.1). The overall response rate (ORR) was 95.3% in the group of patients in whom a response to treatment was assessed and 86.3% for all patients. Twenty patients (17.1% out of 117) achieved a complete response (CR), 81 (69.2%) achieved a partial response (PR), and in 5 patients (4.3%), disease progression was noted (assessed as the best response during treatment). The median PFS in the whole cohort was 36.97 (95% CI 24.5, not reached) months, and the median OS was not reached (95% CI 27.03, not reached). Thirty-six patients died during the follow-up, 10 (8.5%; 27.8% of deaths) due to COVID-19 infection. All grade neutropenia (<jats:italic>n<\/jats:italic>\u2009=\u200987\/117, 74.4%; grade 3 or higher <jats:italic>n<\/jats:italic>\u2009=\u200967\/117, 57.3%) was the most common treatment adverse event. Forty-five patients (38.5%) remained on treatment, and twenty-two (18.8%) completed 24\u00a0months of therapy, while it was discontinued in fifty cases (42.7%). In this real-world setting of early access in very high-risk RR-CLL patients, the VEN-R regimen was associated with shorter median PFS compared with the results of the MURANO trial. This outcome, however, could be attributed to patients\u2019 exposure to SARS-CoV-2 infection and the aggressive course of the disease as very high-risk patients, after multiple lines of prior therapies, were included in the Polish Ministry of Health reimbursement program.<\/jats:p>","DOI":"10.1007\/s00277-023-05304-4","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T06:02:06Z","timestamp":1688191326000},"page":"2119-2126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia\u2014a real-world analysis of the Polish Adult Leukemia Study Group"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-4191","authenticated-orcid":false,"given":"Anita","family":"Sobo\u0144","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Paszkiewicz-Kozik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Pop\u0142awska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Morawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagoda","family":"Tryc-Szponder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Bo\u0142kun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Juda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Majeranowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Iskierka-Ja\u017cd\u017cewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Steckiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Wdowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Budziszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Mara\u0144da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"issue":"5","key":"5304_CR1","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s12185-019-02788-7","volume":"111","author":"Y Kikushige","year":"2020","unstructured":"Kikushige Y (2020) Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. Int J Hematol 111(5):634\u2013641","journal-title":"Int J Hematol"},{"issue":"1","key":"5304_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP et al (2021) Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annal Oncol\u00a0Off J Eur\u00a0Soc Med Oncol \/ ESMO 32(1):23\u201333","journal-title":"Annal Oncol: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"12","key":"5304_CR3","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 96(12):1679\u20131705","journal-title":"Am J Hematol"},{"key":"5304_CR4","doi-asserted-by":"publisher","first-page":"100824","DOI":"10.1016\/j.blre.2021.100824","volume":"49","author":"A Petrackova","year":"2021","unstructured":"Petrackova A, Turcsanyi P, Papajik T, Kriegova E (2021) Revisiting Richter transformation in the era of novel CLL agents. Blood Rev 49:100824","journal-title":"Blood Rev"},{"issue":"12","key":"5304_CR5","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/cancers11121834","volume":"11","author":"B Pu\u0142a","year":"2019","unstructured":"Pu\u0142a B, Go\u0142os A, G\u00f3rniak P, Jamroziak K (2019) Overcoming Ibrutinib resistance in chronic lymphocytic leukemia. Cancers 11(12):1834. https:\/\/doi.org\/10.3390\/cancers11121834","journal-title":"Cancers"},{"issue":"1","key":"5304_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11864-017-0448-2","volume":"18","author":"K Jamroziak","year":"2017","unstructured":"Jamroziak K, Pula B, Walewski J (2017) Current treatment of chronic lymphocytic leukemia. Curr Treat Options Oncol 18(1):5","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"5304_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"4","key":"5304_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"1","key":"5304_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/cpt.553","volume":"101","author":"AW Roberts","year":"2017","unstructured":"Roberts AW, Huang D (2017) Targeting BCL2 With BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin Pharmacol Ther 101(1):89\u201398","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"5304_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C et al (2019) Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol\u202f\u00a0Off J Am\u00a0Soc Clin Oncol\u00a037(4):269\u2013277","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"12","key":"5304_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S et al (2018) Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107\u20131120","journal-title":"N Engl J Med"},{"issue":"9","key":"5304_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED (2016) Venetoclax: First Global Approval. Drugs 76(9):979\u2013987","journal-title":"Drugs"},{"issue":"25","key":"5304_CR13","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745\u20132760","journal-title":"Blood"},{"issue":"8","key":"5304_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF, D\u2019Rozario J, Owen CJ, Assouline S et al (2022) Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab 140(8):839\u2013850. https:\/\/doi.org\/10.1182\/blood.2021015014","journal-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab"},{"key":"5304_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/cancers14030558","volume":"14","author":"B Pu\u0142a","year":"2022","unstructured":"Pu\u0142a B, Pruszczyk K, Pietrusza E, Morawska M, Piszczek W, Kalici\u0144ska E et al (2022) Outcome of SARS-CoV-2-infected polish patients with chronic lymphocytic leukemia. Cancers 14:558. https:\/\/doi.org\/10.3390\/cancers14030558","journal-title":"Cancers"},{"issue":"1","key":"5304_CR16","doi-asserted-by":"publisher","first-page":"e2021042","DOI":"10.4084\/MJHID.2021.042","volume":"13","author":"S Molica","year":"2021","unstructured":"Molica S, Sportoletti P, Di Renzo N, Musto P, Pane F, Di Raimondo F (2021) Venetoclax-rituximab treatment of relapsed\/refractory CLL during the COVID-19 pandemic: a real-life experience in selected central-southern Italian regions. Mediterr J Hematol Infect Dis 13(1):e2021042","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"5304_CR17","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","volume":"34","author":"L Scarf\u00f2","year":"2020","unstructured":"Scarf\u00f2 L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C et al (2020) COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 34(9):2354\u20132363","journal-title":"Leukemia"},{"issue":"18","key":"5304_CR18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.2021011841","volume":"138","author":"LE Roeker","year":"2021","unstructured":"Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS et al (2021) COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood 138(18):1768\u20131773","journal-title":"Blood"},{"issue":"8","key":"5304_CR19","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1038\/s41375-020-0941-7","volume":"34","author":"M F\u00fcrstenau","year":"2020","unstructured":"F\u00fcrstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J et al (2020) COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia 34(8):2225\u20132229","journal-title":"Leukemia"},{"issue":"10","key":"5304_CR20","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/bloodadvances.2019000180","volume":"3","author":"AR Mato","year":"2019","unstructured":"Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams ALM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Christopher P (2019) Fox; A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R\/R CLL. Blood Adv 3(10):1568\u20131573","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05304-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:08:04Z","timestamp":1689232084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05304-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5304"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05304-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"16 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"B.P. served as consultant for Abbvie, Roche, and Sandoz and received honoraria and research funding from Abbvie, Amgen, Gilead, Celgene, and Janssen. EIJ received honoraria from Abbvie, Amgen, Novartis, and Janssen and served as consultant for Abbvie, AstraZeneca, and Sandoz. EPK Speakers\u2019 honoraria and\/or participation in Scientific Advisory Boards: Roche, Sandoz, Takeda, Janssen. JDS: Speakers\u2019 honoraria and\/or participation in Scientific Advisory Boards: Abbvie, Roche, Sandoz, Janssen, Servier. JR Speakers\u2019 Honoraria and participation in Scientific Advisory Boards: Abbvie, Janssen, Roche, Amgen, Celgene\/BMS, Takeda, Sanofi, Pfizer, Novartis. The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}